<DOC>
	<DOCNO>NCT02184325</DOCNO>
	<brief_summary>Study evaluate tolerability safety Kiddi® Pharmaton Fizz effervescent tablet , child 6 14 year , compare give formula improve one reduced mineral content ( qualitatively equivalent first one ) comparator product .</brief_summary>
	<brief_title>Safety Tolerability Kiddi® Pharmaton Fizz Effervescent Tablets Children</brief_title>
	<detailed_description />
	<criteria>Children sex age 6 14 year , inclusive Children , healthy convalescence , prevention treatment marginal vitamin deficit indicate Willingness child parent give write informed consent , accord Good Clinical Practice local regulation Pregnant child exclude Has take medication contain vitamin A D , retinoids , iron 4 week precede study enrolment Pretreatment ( less 2 week prior inclusion trial ) and/or concomitant treatment drug may influence trial symptomatology , may interfere evaluation safety test drug Participation clinical trial within last 4 week concurrent participation another clinical trial Relevant allergy kown hypersensitivity one ingredients investigational drug Has serious disorder may interfere participation trial Malabsorption syndrome , liver and/or renal disease juvenile diabetes Increased calcium blood concentration , increase calciumexcretion Evident state protein deficiency Presence lysinemia ( defect enzyme lysine ketoglutarate reductase )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>